Navigation path

Pharmaceuticals - Union Register

  

Register of orphan medicinal products


GRANTED  

Product information

Pegunigalsidase alfa

EU orphan designation number: EU/3/17/1953   
Active ingredient: Pegunigalsidase alfa
Indication: Treatment of Fabry disease
Sponsor: Protalix B.V
Herikerbergweb 238, Luna ArenA, 1101 CM Amsterdam, Nederland

   Public summary of scientific opinion    

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
14/12/2017 Orphan designation EMA/OD/138/17 (2017)8785 of 12/12/2017